Elecoglipron, also referenced as AZD5004 or ECC5004, is the once-daily oral small-molecule GLP-1 receptor agonist that AstraZeneca licensed from Shanghai-based Eccogene in 2023 and is developing as the backbone of an oral cardiometabolic combination strategy. The drug is not a peptide, but acts on the same receptor as semaglutide and competes directly in the oral GLP-1 race alongside Lilly's orforglipron (Foundayo) and Structure's aleniglipron.
The Phase 2b program met its endpoints in 2026. VISTA (obesity or overweight with comorbidity) and SOLSTICE (type 2 diabetes) both supported a Phase 3 transition, with SOLSTICE showing HbA1c reduction by 26 weeks. A Sunday June 7 ADA 2026 poster added Chinese Phase 1b safety, tolerability, and PK/PD data; the VISTA and SOLSTICE symposium followed Monday June 8.
AstraZeneca advanced elecoglipron into a full Phase 3 program in Q2 2026, confirmed on the Monday July 27 Q2 earnings call. The program comprises the EMBOLD trials in adults with obesity or overweight (with and without type 2 diabetes), the ELUMINATE trials in adults with type 2 diabetes (as monotherapy and in combination with dapagliflozin), and long-term cardiovascular and kidney outcome trials. AstraZeneca plans to develop elecoglipron as an oral combination backbone, including pairings with dapagliflozin for diabetes, chronic kidney disease, and heart failure, and with AZD0780 for dyslipidemia.
Stories here cover elecoglipron trial readouts and AstraZeneca's oral cardiometabolic strategy. See [[astrazeneca]], [[oral-glp-1]], and [[embold]] for adjacent threads.
AstraZeneca (NYSE: AZN) reported Q2 2026 earnings before market open Monday July 27, 2026 with core earnings per share of $2.63 for the three months ended June 30 (+18% constant currency), beating consensus of $2.48. Revenue of $15.38 billion was in line with consensus of $15.39 billion (+5%). Analyst focus on the earnings call centered on the pipeline update: elecoglipron, the oral small-molecule GLP-1 receptor agonist AstraZeneca in-licensed and advanced through Phase 2 VISTA and SOLSTICE (positive data at ADA 2026 Scientific Sessions in June), has moved into a full Phase 3 program in Q2 2026. The Phase 3 program includes the EMBOLD trials in adults with obesity or overweight (with and without type 2 diabetes), the ELUMINATE trials in adults with type 2 diabetes (as monotherapy and in combination with dapagliflozin), and long-term cardiovascular and kidney outcome trials. AstraZeneca is now the third major sponsor competing with Novo Nordisk and Eli Lilly for the oral GLP-1 market alongside oral semaglutide/Ozempic and orforglipron (Foundayo, FDA-approved April 2026). AstraZeneca separately revised the peak sales projection for tozorakimab (experimental respiratory treatment) to above $5 billion from the previous $3 billion estimate. AZN shares rose approximately 1.7% in London Monday morning trading.
BioSpace's reaction to AstraZeneca's elecoglipron VISTA Phase 2b readout (10.5% weight loss at 26 weeks) framed it as 'relatively underwhelming' next to Structure Therapeutics' aleniglipron (up to 16.3% at 44 weeks, Nature Medicine publication on Friday). Both are oral small-molecule GLP-1s with Phase 3 plans for the second half of 2026, but elecoglipron's lower number gives Structure a clearer differentiation story heading into its Phase 3 start. AstraZeneca will lean on its combination strategy with dapagliflozin and AZD0780 to position elecoglipron.
AstraZeneca presented VISTA Phase 2b data at ADA 2026 with simultaneous Lancet publication. In adults with obesity or overweight plus comorbidity, oral elecoglipron 75 mg produced 10.5% mean weight loss at 26 weeks versus 0.6% on placebo, continuing to 11.8% by 36 weeks, alongside blood-pressure and inflammation reductions. The companion SOLSTICE T2D trial showed 1.9-point HbA1c reductions with 90% reaching HbA1c under 7% and 7.7% weight loss. AstraZeneca announced an extensive Phase 3 program covering obesity, T2D, and cardiovascular and kidney outcome trials.
Monday's data sharpened the oral GLP-1 competitive map. Lilly's Foundayo (orforglipron) leads with a Phase 3 head-to-head win over oral semaglutide and a Q2 FDA filing pending. Structure's aleniglipron sits closest, with 16.3% Phase 2b weight loss and Nature Medicine publication on Friday. AstraZeneca's elecoglipron just cleared Phase 2b. Chinese entrants Hengrui-Kailera (ribupatide, HRS-7535) added Phase 2 and 3 readouts. Novo's Wegovy pill remains the only currently-approved oral, but the next-wave field is now broad and head-to-head data are arriving fast.
Eccogene and AstraZeneca presented a Sunday June 7 poster on the safety, tolerability, and PK/PD of elecoglipron (AZD5004/ECC5004) in Chinese adults with obesity or overweight, with or without type 2 diabetes. The Monday June 8 symposium covers the VISTA Phase 2b obesity readout and the SOLSTICE Phase 2b trial in type 2 diabetes, where the oral GLP-1 reduced HbA1c at 26 weeks and supported a Phase 3 transition. AstraZeneca plans to develop elecoglipron as an oral combination backbone alongside dapagliflozin in diabetes/CKD/HF and AZD0780 in dyslipidemia.
Eccogene and AstraZeneca will present multiple datasets for the oral small-molecule GLP-1 receptor agonist elecoglipron (AZD5004/ECC5004) at ADA 2026 on June 7-8, including a late-breaking Phase 1b study conducted in China, plus the Phase 2b VISTA trial in obesity (which met its primary endpoints) and the SOLSTICE Phase 2b trial in type 2 diabetes. The slate deepens the oral-GLP-1 contest forming below Lilly's orforglipron.
AstraZeneca's eleglipron (formerly elecoglipron / AZD5004 / ECC5004), the oral small-molecule GLP-1 agonist licensed from Eccogene in 2023, met primary endpoints in two Phase 2b trials with results detailed at the company's April 29 Q1 print: VISTA (NCT06579092, 310 obesity patients, 26-week weight loss) and SOLSTICE (NCT06579105, 406 type-2 diabetes patients, 26-week HbA1c change vs semaglutide and placebo). AstraZeneca held back exact weight-loss numbers, framing the molecule as 'very competitive,' with full data scheduled for the American Diabetes Association meeting in June. The company committed to a comprehensive Phase 3 program targeting both weight-loss efficacy and outcome benefits, with monotherapy and fixed-dose combination programs anchored against the SYH2082 dual-agonist and LiquidGel monthly-dosing platform from the $18.5B CSPC Pharmaceuticals collaboration.